Why the study?
Does sacubitril/valsartan improve outcomes and renal function in patients with HFrEF?
Does sacubitril/valsartan improve outcomes and renal function in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
Sacubitril/valsartan provides renal protection and improves outcomes in HFrEF patients, particularly those tolerating escalating doses, regardless of baseline CKD status.
Long-term S/V therapy is associated with improved outcomes and renal protection in patients with HFrEF. This effect is more pronounced in patients who tolerate escalating doses. The positive effects of the drug are maintained in both CKD and preserved renal function. Future research may study the safety and underlying causes of current protection.
No takes yet. Share an insight, caveat, or question.
Palazzuoli et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: